Oxymetazoline
Oxymetazoline hydrochloride
Brand names:Afrin, Vicks Sinex, Rhofade
A topical alpha-adrenergic agonist used as a long-acting nasal decongestant and as a topical hemostatic agent for epistaxis. Oxymetazoline produces 8 to 12 hours of vasoconstriction with a single dose, longer than phenylephrine. Operationally important in tactical and deployment medicine for epistaxis control and severe nasal congestion.
Pharmacology and Actions
Oxymetazoline is a selective alpha-1 and alpha-2 adrenergic agonist with potent topical vasoconstrictor effects. The alpha-2 activity contributes to the longer duration compared to phenylephrine. Applied topically to nasal mucosa, the drug produces rapid and sustained vasoconstriction with associated reduction in mucosal swelling and bleeding. Systemic absorption is minimal with standard nasal use but can be significant with excessive or broken-skin application.
Indications
- Severe nasal congestion (short-term use only)
- Anterior epistaxis (topical hemostatic agent)
- Adjunct to nasal packing for epistaxis control
- Operational sinus pressure management at altitude (short-term)
- Rosacea (Rhofade topical cream formulation)
Absolute Contraindications
- Known oxymetazoline or sympathomimetic allergy
- Use beyond 3 days continuous duration (rebound congestion)
- Concurrent MAOI use within 14 days
- Severe hypertension or coronary artery disease (relative for systemic absorption)
Precautions and Side Effects
Rebound congestion (rhinitis medicamentosa) is the most common adverse effect and develops with use beyond 3 to 5 days. Strict 3-day maximum is operationally important. Burning, stinging, and dryness at application site can occur. Systemic absorption from excessive use can cause hypertension, tachycardia, and CNS effects. Pediatric ingestion of oxymetazoline solution can cause severe systemic toxicity including profound hypotension, bradycardia, and coma; secure these preparations from pediatric access.
Adult Dosing
Pediatric Dosing
Pediatric nasal spray for ages 6 and older: 2 to 3 sprays per nostril every 10 to 12 hours, maximum 2 doses per 24 hours, maximum 3 days. Avoid in children under 6.
Pharmacokinetics
Peak Effect: Topical nasal: 30 minutes
Duration: 8 to 12 hours (longer than phenylephrine)
Storage and Handling
Store at controlled room temperature (15 to 30 degrees Celsius). Protect from light. Secure from pediatric access; ingestion of nasal spray bottles by young children has caused severe systemic toxicity.
Reconstitution:
Nasal spray and topical cream require no reconstitution.
TCCC and TECC Role
Oxymetazoline is operationally important in tactical and TEMS settings primarily for anterior epistaxis management. The topical vasoconstrictor effect provides rapid hemostasis when applied to a soaked cotton pledget placed in the affected nostril. This technique is taught in standard TEMS and emergency medicine education and is more effective than mechanical pressure alone for many anterior bleeds. The drug also has deployment medicine utility for severe nasal congestion during operations, though the 3-day limit must be respected.
Oxymetazoline is the drug for epistaxis control before more invasive interventions. The technique is straightforward: soak a cotton pledget or strip of gauze in Afrin, place it in the bleeding nostril, and apply external pressure for 10 to 15 minutes. The combination of mechanical pressure and topical vasoconstriction stops most anterior bleeds. For nasal congestion, the operational advantage over phenylephrine is duration (8 to 12 hours vs 4 hours), but the rebound congestion risk is also greater. Strict 3-day limit prevents rhinitis medicamentosa.
Continuing oxymetazoline use beyond 3 days, which produces rhinitis medicamentosa, a rebound congestion syndrome that can take weeks to resolve and is worse than the original symptoms. Educate users about the 3-day limit. The other common error is failing to use oxymetazoline for anterior epistaxis when mechanical pressure alone has not controlled bleeding; this is a high-value intervention that should be routinely available in tactical and EMS kits.
This drug profile is provided as educational reference material for trained medical providers. It is not medical advice, not a substitute for formal training, and not a substitute for current published guidelines or medical direction.
Drug administration is governed by your scope of practice, agency standing orders, medical director protocols, and applicable state and federal regulations. Controlled substances are subject to additional handling, accountability, and documentation requirements per DEA and state law. Always verify dosing, indications, contraindications, and route of administration against current published guidelines and your local protocols before administration.
If this content is being viewed during a medical emergency, call 911 immediately and follow the direction of your local emergency dispatch and medical control. Do not use this reference as a substitute for emergency medical services.
Drug information evolves. Last reviewed dates and source citations are provided for each entry. Confirm currency against the cited source before clinical use.
Penn Tactical Solutions publishes this reference for educational purposes. PTS does not provide medical direction and does not assume responsibility for clinical decisions made in the field. Clinical responsibility rests with the administering provider, their medical director, and their agency.
Educational reference for trained medical providers. Not medical advice. Not a substitute for formal training, current published guidelines, or medical direction. Drug administration is governed by your scope of practice, agency standing orders, medical director protocols, and applicable state and federal regulations. Controlled substances require additional storage, accountability, and documentation per DEA and state law.
In a medical emergency, call 911. This reference is not a substitute for emergency medical services.
Verify dosing, indications, and contraindications against current published guidelines and your local protocols before administration. Confirm content currency against the source citation. Penn Tactical Solutions does not provide medical direction. Clinical responsibility rests with the administering provider, their medical director, and their agency.
Oxymetazoline
| IN | Nasal spray 0.05 percent: 2 to 3 sprays per nostril every 10 to 12 hours. Maximum 2 doses per 24 hours. Limit total continuous use to 3 days to avoid rebound congestion. (5 to 10 minutes (nasal vasoconstriction)) |